AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca is conducting a Phase III clinical trial titled ‘A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event.’ The study aims to evaluate the effectiveness of AZD0780, an oral PCSK9 inhibitor, in reducing major adverse cardiovascular events (MACE-PLUS) in patients with existing ASCVD or those at high risk for such events.
Intervention/Treatment: The study tests AZD0780, an oral drug designed to inhibit PCSK9, which is expected to lower the risk of cardiovascular events. Participants will receive either AZD0780 or a placebo daily.
Study Design: This is an international, multi-center, randomized, double-blind, placebo-controlled study with a parallel-group design. It involves quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary goal is treatment-focused.
Study Timeline: The study began on May 30, 2025, with the latest update submitted on September 4, 2025. These dates are crucial as they mark the study’s progress and updates, indicating its current recruiting status.
Market Implications: This update could potentially boost AstraZeneca’s stock performance by showcasing their commitment to advancing cardiovascular treatment. Positive results may enhance investor confidence and position AstraZeneca favorably against competitors in the cardiovascular drug market.
The study is ongoing, and further details are available on the ClinicalTrials portal.